Cardiff Oncology Inc.

NASDAQ: CRDF · Real-Time Price · USD
2.41
-0.03 (-1.23%)
At close: Aug 15, 2025, 10:06 AM

Cardiff Oncology Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
683K 488K 386K 359K
Cost of Revenue
n/a n/a 200K 500K
Gross Profit
683K 488K 186K -141K
Operating Income
-48.65M -45.41M -39.9M -28.86M
Interest Income
3.26M 4.07M 1.58M 264K
Pretax Income
-45.45M -41.44M -38.7M -28.29M
Net Income
-45.43M -41.44M -37.51M -27.74M
Selling & General & Admin
12.48M 13.04M 13.18M 11.84M
Research & Development
36.85M 32.86M 27.11M 17.38M
Other Expenses
n/a n/a -383K 15K
Operating Expenses
49.33M 45.9M 40.29M 29.21M
Interest Expense
n/a n/a n/a n/a
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
49.33M 45.9M 40.29M 29.21M
Income Tax Expense
-24K n/a -1.2M -549K
Shares Outstanding (Basic)
47.65M 44.68M 43.6M 39.03M
Shares Outstanding (Diluted)
47.65M 44.68M 43.6M 39.03M
EPS (Basic)
-0.95 -0.93 -0.86 -0.71
EPS (Diluted)
-0.95 -0.93 -0.86 -0.71
EBITDA
-48.25M -45.01M -39.67M -28.4M
EBIT
-48.65M -45.41M -39.9M -28.86M
Depreciation & Amortization
404K 398K 200K 500K